

## E.I. DU PONT DE NEMOURS & CO. (INC.) MEDICAL PRODUCTS DEPARTMENT

December 7, 1990

United States Nuclear Regulatory Commission Attn: Charles E. MacDonald, Chief Transportation Branch Division of Safeguards and Transportation, NMSS Washington, D.C. 20555

Reference: QA Program Approval Number 0384

Dear Mr. MacDonald:

This is a request for a new Quality Assurance Program Approval for Radioactive Material Packages to authorize the Du Pont Boston operations program that was previously covered under the above-referenced approval.

71-0711

NTA2'

On January 1, 1991, a new company will be officially formed by a Joint Venture between the two major corporations, Du Pont and Merck. The name of the company will be changing from Du Pont to the Du Pont Merck Pharmaceutical Company and will include the operations at 331 Treble Cove Road, North Billerica, Massachusetts. The existing Du Pont operations at 549 Albany Street, Boston, MA, including the three Du Pont operations that will remain at the Billerica Site, will not be affected by this change.

However, after consulting with you, it has been deemed necessary to establish a separate Quality Assurance Program for the Du Pont operations in Boston.

Therefore, effective January 1, 1991, we request a new Quality Assurance Program Approval be issued for the Boston Site at the following address:

Du Pont Biotechnology Systems 549 Albany Street Boston, Massachusetts 02118

A revised version of the Quality Assurance Program has been written and is enclosed for your review.

I have enclosed a check in the amount of \$180.00 in payment of the approval processing fee as specified for License Category 10B in the regulations of Title 10 CFR Part 170, Section 170.31.

Please contact me if you require any additional information.

Sincerely,

Francis C Roje

Francis E. Roy Jr. Health Physicist Telephone: (508) 671-8242

MEDICAL PRODUCTS DEPARTMENT

40. 00331 Treble Cove Road, No. Billerica, MA 01862 Telephone 508-667-9531